{"organizations": [], "uuid": "1cd7c603808968c5e2c88abab6260bbf834b9a00", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-immunomedics-royalty-pharma-announ/brief-immunomedics-royalty-pharma-announce-royalty-funding-and-stock-purchase-agreements-totalling-250-mln-idUSFWN1P30LU", "country": "US", "domain_rank": 408, "title": "BRIEF-Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T15:40:00.000+02:00", "replies_count": 0, "uuid": "1cd7c603808968c5e2c88abab6260bbf834b9a00"}, "author": "", "url": "https://www.reuters.com/article/brief-immunomedics-royalty-pharma-announ/brief-immunomedics-royalty-pharma-announce-royalty-funding-and-stock-purchase-agreements-totalling-250-mln-idUSFWN1P30LU", "ord_in_thread": 0, "title": "BRIEF-Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "royalty pharma announce royalty funding", "sentiment": "negative"}, {"name": "royalty pharma announce royal", "sentiment": "negative"}, {"name": "immunomedics", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "immunomedics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "immunomedics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 8, 2018 / 1:40 PM / Updated 11 minutes ago BRIEF-Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln Reuters Staff \nJan 8 (Reuters) - Immunomedics Inc: \n* IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION \n* IMMUNOMEDICS INC - ROYALTY PHARMA ACQUIRES ROYALTY RIGHTS ON GLOBAL NET SALES OF SACITUZUMAB GOVITECAN (IMMU-132) ACROSS ALL INDICATIONS FOR $175 MILLION \n* IMMUNOMEDICS INC - ROYALTY PHARMA HAS ALSO PURCHASED $75 MILLION IN COMMON STOCK OF IMMUNOMEDICS, AT $17.15 PER SHARE \n* IMMUNOMEDICS - TRANSACTION WILL PROVIDE SUFFICIENT CASH TO FUND OPERATIONS INTO 2020 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-08T15:40:00.000+02:00", "crawled": "2018-01-08T15:58:34.007+02:00", "highlightTitle": ""}